Yimei Li

Summary

Affiliation: University of Pennsylvania
Country: USA

Publications

  1. pmc Suspension of accrual in phase II cancer clinical trials
    Yimei Li
    Department of Biostatistics and Epidemiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA Division of Oncology, The Children s Hospital of Philadelphia, Philadelphia, PA, USA
    Clin Trials 12:128-38. 2015
  2. doi request reprint Modeling smoking cessation data with alternating states and a cure fraction using frailty models
    Yimei Li
    Department of Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, PA 19104 6021, USA
    Stat Med 29:627-38. 2010
  3. pmc Establishing a high-risk neuroblastoma cohort using the Pediatric Health Information System Database
    Ami V Desai
    Division of Oncology, The Children s Hospital of Philadelphia, Philadelphia, Pennsylvania Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania Center for Pharmacoepidemiology Research and Training, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania
    Pediatr Blood Cancer 61:1129-31. 2014
  4. pmc Merging Children's Oncology Group Data with an External Administrative Database Using Indirect Patient Identifiers: A Report from the Children's Oncology Group
    Yimei Li
    Department of Biostatistics and Epidemiology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, United States of America
    PLoS ONE 10:e0143480. 2015
  5. pmc Dexrazoxane exposure and risk of secondary acute myeloid leukemia in pediatric oncology patients
    Alix E Seif
    Division of Oncology, The Children s Hospital of Philadelphia, Philadelphia, Pennsylvania Department of Pediatrics, The Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania
    Pediatr Blood Cancer 62:704-9. 2015
  6. pmc Induction mortality, ATRA administration, and resource utilization in a nationally representative cohort of children with acute promyelocytic leukemia in the United States from 1999 to 2009
    Brian T Fisher
    Division of Infectious Diseases, The Children s Hospital of Philadelphia, Philadelphia, Pennsylvania Center for Pediatric Clinical Effectiveness, The Children s Hospital of Philadelphia, Philadelphia, Pennsylvania Department of Pediatrics, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania
    Pediatr Blood Cancer 61:68-73. 2014
  7. doi request reprint Supportive care utilization and treatment toxicity in children with Down syndrome and acute lymphoid leukaemia at free-standing paediatric hospitals in the United States
    Elizabeth G Salazar
    Department of Pediatrics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA
    Br J Haematol 174:591-9. 2016
  8. pmc Early discharge as a mediator of greater ICU-level care requirements in patients not enrolled on the AAML0531 clinical trial: a Children's Oncology Group report
    Kelly D Getz
    The Children s Hospital of Philadelphia, 3535 Market Street, Philadelphia, Pennsylvania, 19104
    Cancer Med 5:2412-6. 2016
  9. pmc A comparison of resource utilization following chemotherapy for acute myeloid leukemia in children discharged versus children that remain hospitalized during neutropenia
    Kelly D Getz
    Division of Oncology, The Children s Hospital of Philadelphia, Philadelphia, Pennsylvania
    Cancer Med 4:1356-64. 2015
  10. pmc Comparison of administrative/billing data to expected protocol-mandated chemotherapy exposure in children with acute myeloid leukemia: A report from the Children's Oncology Group
    Tamara P Miller
    Division of Oncology, The Children s Hospital of Philadelphia, Philadelphia, Pennsylvania
    Pediatr Blood Cancer 62:1184-9. 2015

Collaborators

Detail Information

Publications32

  1. pmc Suspension of accrual in phase II cancer clinical trials
    Yimei Li
    Department of Biostatistics and Epidemiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA Division of Oncology, The Children s Hospital of Philadelphia, Philadelphia, PA, USA
    Clin Trials 12:128-38. 2015
    ..This article aims to evaluate various options for accrual suspension and illustrate how the suspension strategy affects operating characteristics of the trial...
  2. doi request reprint Modeling smoking cessation data with alternating states and a cure fraction using frailty models
    Yimei Li
    Department of Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, PA 19104 6021, USA
    Stat Med 29:627-38. 2010
    ..A simulation study suggests that the estimates have little bias and that their 95 per cent confidence intervals have nearly nominal coverage in samples of practical size...
  3. pmc Establishing a high-risk neuroblastoma cohort using the Pediatric Health Information System Database
    Ami V Desai
    Division of Oncology, The Children s Hospital of Philadelphia, Philadelphia, Pennsylvania Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania Center for Pharmacoepidemiology Research and Training, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania
    Pediatr Blood Cancer 61:1129-31. 2014
    ..1%; positive predictive value (PPV) 96.1%]. This cohort provides a data source for future comparative effectiveness and clinical epidemiology studies in high-risk neuroblastoma patients...
  4. pmc Merging Children's Oncology Group Data with an External Administrative Database Using Indirect Patient Identifiers: A Report from the Children's Oncology Group
    Yimei Li
    Department of Biostatistics and Epidemiology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, United States of America
    PLoS ONE 10:e0143480. 2015
    ..Merging without direct patient identifiers would provide additional patient privacy protections. We sought to develop and validate a matching algorithm that uses only indirect patient identifiers...
  5. pmc Dexrazoxane exposure and risk of secondary acute myeloid leukemia in pediatric oncology patients
    Alix E Seif
    Division of Oncology, The Children s Hospital of Philadelphia, Philadelphia, Pennsylvania Department of Pediatrics, The Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania
    Pediatr Blood Cancer 62:704-9. 2015
    ..Published data about dexrazoxane-associated secondary AML are limited and conflicting. We sought to estimate the secondary AML risk in children receiving dexrazoxane after anthracycline exposure...
  6. pmc Induction mortality, ATRA administration, and resource utilization in a nationally representative cohort of children with acute promyelocytic leukemia in the United States from 1999 to 2009
    Brian T Fisher
    Division of Infectious Diseases, The Children s Hospital of Philadelphia, Philadelphia, Pennsylvania Center for Pediatric Clinical Effectiveness, The Children s Hospital of Philadelphia, Philadelphia, Pennsylvania Department of Pediatrics, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania
    Pediatr Blood Cancer 61:68-73. 2014
    ....
  7. doi request reprint Supportive care utilization and treatment toxicity in children with Down syndrome and acute lymphoid leukaemia at free-standing paediatric hospitals in the United States
    Elizabeth G Salazar
    Department of Pediatrics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA
    Br J Haematol 174:591-9. 2016
    ..These findings highlight the importance of investigating the impact of these care variations and developing specific supportive care guidelines for this population. ..
  8. pmc Early discharge as a mediator of greater ICU-level care requirements in patients not enrolled on the AAML0531 clinical trial: a Children's Oncology Group report
    Kelly D Getz
    The Children s Hospital of Philadelphia, 3535 Market Street, Philadelphia, Pennsylvania, 19104
    Cancer Med 5:2412-6. 2016
    ..94), whereas the indirect effect mediated through early discharge was not (aOR = 1.07, 95% CI: 0.95, 1.19). Factors other than postchemotherapy discharge strategy drive the difference in ICU utilization by trial enrollment status. ..
  9. pmc A comparison of resource utilization following chemotherapy for acute myeloid leukemia in children discharged versus children that remain hospitalized during neutropenia
    Kelly D Getz
    Division of Oncology, The Children s Hospital of Philadelphia, Philadelphia, Pennsylvania
    Cancer Med 4:1356-64. 2015
    ..Despite similar inpatient mortality to standard discharge patients, early discharge patients may be at greater risk for life-threatening chemotherapy-related complications, including infections...
  10. pmc Comparison of administrative/billing data to expected protocol-mandated chemotherapy exposure in children with acute myeloid leukemia: A report from the Children's Oncology Group
    Tamara P Miller
    Division of Oncology, The Children s Hospital of Philadelphia, Philadelphia, Pennsylvania
    Pediatr Blood Cancer 62:1184-9. 2015
    ....
  11. pmc Outcome of pediatric acute myeloid leukemia patients receiving intensive care in the United States
    Shannon L Maude
    1Division of Oncology, The Children s Hospital of Philadelphia, Philadelphia, PA 2Department of Pediatrics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 3Department of Anesthesia and Critical Care Medicine, The Children s Hospital of Philadelphia, Philadelphia, PA 4Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 5Division of Infectious Diseases, The Children s Hospital of Philadelphia, Philadelphia, PA 6Center for Pediatric Clinical Effectiveness, The Children s Hospital of Philadelphia, Philadelphia, PA 7Bristol Myers Squibb, Hopewell, NJ 8Division of Haematology Oncology and Program in Child Health Evaluative Sciences, The Hospital for Sick Children, Toronto, ON, Canada 9Department of Biostatistics and Epidemiology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 10Division of Pediatric Critical Care Medicine, Department of Pediatrics and Public Health Sciences, Penn State Hershey Milton S Hershey Medical Center, Hershey, PA
    Pediatr Crit Care Med 15:112-20. 2014
    ..Our objective was to determine hospital mortality of pediatric acute myeloid leukemia patients requiring intensive care...
  12. pmc Establishment of an 11-year cohort of 8733 pediatric patients hospitalized at United States free-standing children's hospitals with de novo acute lymphoblastic leukemia from health care administrative data
    Brian T Fisher
    Division of Infectious Diseases Center for Pediatric Clinical Effectiveness, The Children s Hospital of Philadelphia Department of Pediatrics Center for Clinical Epidemiology and Biostatistics, the Perelman School of Medicine at the University of Pennsylvania Division of Oncology, The Children s Hospital of Philadelphia Department of Biostatistics and Epidemiology, The Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
    Med Care 52:e1-6. 2014
    ..Despite cooperative group therapeutic trials, there remains a paucity of large cohort data on which to conduct epidemiology and comparative effectiveness research studies...
  13. pmc Variation in Risk of Hospital-Onset Clostridium difficile Infection Across β-Lactam Antibiotics in Children With New-Onset Acute Lymphoblastic Leukemia
    Brian T Fisher
    Division of Infectious Diseases Center for Pediatric Clinical Effectiveness, The Children s Hospital of Philadelphia, Pennsylvania Department of Pediatrics, and Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia
    J Pediatric Infect Dis Soc 3:329-35. 2014
    ..Antibiotic exposure is common among children with leukemia. However, limited data exist regarding the risk of Clostridium difficile infection (CDI) across anti-pseudomonal β-lactam antibiotics commonly used for fever and neutropenia...
  14. pmc Association of weekend admission with hospital length of stay, time to chemotherapy, and risk for respiratory failure in pediatric patients with newly diagnosed leukemia at freestanding US children's hospitals
    Elizabeth K Goodman
    Division of Oncology, The Children s Hospital of Philadelphia, Philadelphia, Pennsylvania
    JAMA Pediatr 168:925-31. 2014
    ..In adult patients with leukemia, weekend admission is associated with increased inpatient mortality. It is unknown whether weekend diagnostic admissions in pediatric patients with leukemia demonstrate similar adverse outcomes...
  15. pmc Patient and hospital factors associated with induction mortality in acute lymphoblastic leukemia
    Alix E Seif
    Division of Oncology, The Children s Hospital of Philadelphia, Philadelphia, Pennsylvania
    Pediatr Blood Cancer 61:846-52. 2014
    ..We sought to ascertain patient- and hospital-level factors associated with induction mortality...
  16. pmc Volume-Outcome Relationships in Pediatric Acute Lymphoblastic Leukemia: Association Between Hospital Pediatric and Pediatric Oncology Volume With Mortality and Intensive Care Resources During Initial Therapy
    Jennifer J Wilkes
    Division of Oncology, The Children s Hospital of Philadelphia, Philadelphia, PA Center for Pediatric Clinical Effectiveness, The Children s Hospital of Philadelphia, Philadelphia, PA Leonard Davis Institute of Health Economics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA Electronic address
    Clin Lymphoma Myeloma Leuk 16:404-410.e1. 2016
    ..We hypothesized an inverse relationship between volume and these outcomes...
  17. pmc Treatment of Osteonecrosis in Children and Adolescents With Acute Lymphoblastic Leukemia
    Mallorie B Heneghan
    Department of General Pediatrics, The Children s Hospital of Philadelphia, Philadelphia, PA Electronic address
    Clin Lymphoma Myeloma Leuk 16:223-229.e2. 2016
    ..Cure rates for acute lymphoblastic leukemia (ALL) have improved, but as therapy has intensified, the burden of osteonecrosis (ON) has increased. Limited data exist regarding surgical interventions for pediatric ALL patients with ON...
  18. doi request reprint Resource Utilization and Toxicities After Carboplatin/Etoposide/Melphalan and Busulfan/Melphalan for Autologous Stem Cell Rescue in High-Risk Neuroblastoma Using a National Administrative Database
    Ami V Desai
    Division of Oncology, The Children s Hospital of Philadelphia, Philadelphia, Pennsylvania
    Pediatr Blood Cancer 63:901-7. 2016
    ..Resources required to support patients treated with ASCR conditioning regimens [carboplatin/etoposide/melphalan (CEM) and busulfan/melphalan (BuMel)] have not been directly compared...
  19. pmc Leveraging administrative data to monitor rituximab use in 2875 patients at 42 freestanding children's hospitals across the United States
    Marko Kavcic
    Division of Oncology, Center for Pediatric Clinical Effectiveness, The Children s Hospital of Philadelphia, and Department of Pediatrics, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    J Pediatr 162:1252-8, 1258.e1. 2013
    ..To describe the pharmacoepidemiology of rituximab use in children and to estimate the frequency of infectious events within a 1-year period after rituximab exposure...
  20. pmc Bortezomib Inpatient Prescribing Practices in Free-Standing Children's Hospitals in the United States
    Amanda M DiNofia
    Division of Oncology, The Children s Hospital of Philadelphia, Philadelphia, Pennsylvania, United States of America
    PLoS ONE 11:e0151362. 2016
    ..Bortezomib use in pediatrics is increasing for a variety of diseases. Variation in use exists across institutions. Further studies are needed to characterize bortezomib's efficacy in pediatric diseases. ..
  21. pmc Assessing the fit of parametric cure models
    E Paul Wileyto
    Department of Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, PA 19104, USA
    Biostatistics 14:340-50. 2013
    ..We derive the asymptotic distribution of the residuals and evaluate their performance by simulation in a range of parametric models. We apply our approach to data from a smoking cessation drug trial...
  22. doi request reprint Prediction of individual long-term outcomes in smoking cessation trials using frailty models
    Yimei Li
    Division of Oncology, The Children s Hospital of Philadelphia and University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    Biometrics 67:1321-9. 2011
    ..Comparisons of actual smoking status at one year with predictions from our model and from a variety of empirical methods suggest that our method gives excellent predictions...
  23. pmc Comparing Analytic Methods for Longitudinal GWAS and a Case-Study Evaluating Chemotherapy Course Length in Pediatric AML. A Report from the Children's Oncology Group
    Marijana Vujkovic
    Division of Oncology, Children s Hospital of Philadelphia Philadelphia, PA, USA
    Front Genet 7:139. 2016
    ..We therefore recommend PC-LMEM as a robust analytic approach for GWAS of longitudinal data in unrelated populations. ..
  24. pmc Comparison of in-patient costs for children treated on the AAML0531 clinical trial: A report from the Children's Oncology Group
    Kelly D Getz
    The Children s Hospital of Philadelphia, Philadelphia, Pennsylvania
    Pediatr Blood Cancer 62:1775-81. 2015
    ....
  25. pmc Variation in hospital antibiotic prescribing practices for children with acute lymphoblastic leukemia
    Brian T Fisher
    Division of Infectious Diseases, The Children s Hospital of Philadelphia, Philadelphia, PA 19104, USA fi
    Leuk Lymphoma 54:1633-9. 2013
    ..Antibiotic use for children with newly diagnosed ALL varies widely across children's hospitals and is not explained by demographics or illness severity...
  26. pmc A Bayesian approach for unplanned sample sizes in phase II cancer clinical trials
    Yimei Li
    Division of Oncology, The Children s Hospital of Philadelphia, PA 19104, USA
    Clin Trials 9:293-302. 2012
    ..The requirement to examine the outcome at a prespecified sample size (SS) can be problematic, because the attained SS often differs from the planned SS...
  27. pmc Predictors of antiemetic alteration in pediatric acute myeloid leukemia
    Jason L Freedman
    Division of Oncology, The Children s Hospital of Philadelphia, Philadelphia, Pennsylvania
    Pediatr Blood Cancer 61:1798-805. 2014
    ..We aimed to describe such factors in children receiving treatment for acute myeloid leukemia (AML)...
  28. pmc Statistical analysis of daily smoking status in smoking cessation clinical trials
    Yimei Li
    Division of Oncology, The Children s Hospital of Philadelphia and Department of Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, PA 19104, USA
    Addiction 106:2039-46. 2011
    ..We present an alternative approach that analyzes the entire sequence of daily smoking status observations...
  29. pmc The impact of dexamethasone and prednisone on sleep in children with acute lymphoblastic leukemia
    Lauren C Daniel
    Division of Oncology, The Children s Hospital of Philadelphia, 34th and Civic Center Blvd, CTRB 10 300, Philadelphia, PA, 19104, USA
    Support Care Cancer 24:3897-906. 2016
    ..The current study tested the hypothesis that dexamethasone and prednisone differentially affect sleep in children with ALL to understand how these medications contribute to health-related quality of life (HRQL)...
  30. doi request reprint Carboplatin Rechallenge After Hypersensitivity Reactions in Pediatric Patients With Low-Grade Glioma
    Amish C Shah
    Division of Oncology, The Children s Hospital of Philadelphia, Philadelphia, Pennsylvania
    Pediatr Blood Cancer 63:21-6. 2016
    ..Rechallenging patients is an option that must balance the risks of repeat allergic reaction to the benefits of retaining an effective anti-tumor regimen...
  31. pmc The impact of chemotherapy shortages on COG and local clinical trials: a report from the Children's Oncology Group
    Elizabeth G Salazar
    Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania
    Pediatr Blood Cancer 62:940-4. 2015
    ..Oncology drug shortage is associated with increased patient adverse events and decreased enrollment on clinical trials for adult patients; however, the impact of oncology drug shortages has not been well studied in children with cancer...
  32. pmc Induction mortality and resource utilization in children treated for acute myeloid leukemia at free-standing pediatric hospitals in the United States
    Marko Kavcic
    Division of Oncology, The Children s Hospital of Philadelphia, Philadelphia, PA, USA
    Cancer 119:1916-23. 2013
    ..Moreover, these trials likely underreport the clinical toxicities experienced by patients...